在大脑缺血症治疗中,贾斯米诺伊丁和乌尔索多西胆酸的模块化协同机制
Jingai Wang1, Qikai Niu1, Yanan Yu2
1Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Biomedicines
|April 29, 2025
概括
贾斯米诺伊丁和ursodeoxycholic酸通过调节关键蛋白质和通路来协同治疗脑缺血. 这种组合疗法为减少脑损伤提供了一种新的方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 系统生物学 系统生物学
背景情况:
- 大脑缺血 (CI) 是一个重大的健康挑战.
- 贾斯米诺伊丁 (JA) 和乌尔索多胆酸 (UA) 在CI治疗中显示出潜在的协同效应.
- 对JA和UA (JU) 对CI的联合疗效的确切机制尚不清楚.
研究的目的:
- 使用驱动诱导模块查 (DiMS) 策略,阐明用于脑缺血 (CI) 的联合JA和UA (JU) 治疗的协同机制.
- 确定关键的分子参与者和参与JU对CI的协同治疗效应的途径.
主要方法:
- 利用基于网络近距离和拓的方法在抗缺血病微阵列数据集上识别协同模块和驱动基因.
- 建立了一个中脑动脉阻塞/再输 (MCAO/R) 鼠标模型,以评估JA,UA和JU的体内疗效.
- 评估了心脏病发作量,神经缺陷评分,以及通过西式涂抹检测的关键蛋白质表达.
主要成果:
- 确定了三个协同作用模块和12个驱动基因,主要涉及PI3K-Akt,MAPK通路和actin细胞骨调节.
- 证明,与单个治疗相比,JU在MCAO/R大鼠中显著降低了心脏病发作量和神经缺陷得分.
- 确认JU在体内调节了CUL3,FN1,ITGA4和NRF1的表达.
结论:
- 通过调节FN1,CUL3,ITGA4和NRF1.1,JU对脑缺血-再输液损伤产生协同作用.
- 组合疗法诱导PI3K-Akt,MAPK和actin细胞骨通路,有助于其治疗效益.
- 迪姆斯策略为揭示组合疗法的机制提供了一种新且有效的方法.
更多相关视频
09:53Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
235
08:44Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
Published on: September 1, 2016
8.8K
相关概念视频
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
577
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
577
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
329
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
329
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.5K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.5K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
486
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
486
01:26Anticholinesterase Agents: Poisoning and Treatment
759
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
759
01:19Depolarizing Blockers: Pharmocokinetics
296
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
296